These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9689881)

  • 1. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the inapplicability of certain therapeutic guidelines in practice: the example of reimbursement for hypolipidemic agents in Belgium].
    Scheen AJ
    Rev Med Liege; 2000 Apr; 55(4):260-4. PubMed ID: 10909311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmaco-economic aspects of hypolipidemic treatment].
    Scheen AJ
    Rev Med Liege; 1997; 52(1):16-21. PubMed ID: 9064710
    [No Abstract]   [Full Text] [Related]  

  • 4. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 5. [Broader indication for treatment with statins; the 'heart protection study'].
    Stalenhoef AF; Stuyt PM
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1921-3. PubMed ID: 12404905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].
    Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K
    Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
    Szucs TD; Gutzwiller F
    Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of drug treatment: for which patients is it costeffective to lower cholesterol?
    Jönsson B
    Lancet; 2001 Oct; 358(9289):1251-6. PubMed ID: 11675082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V; Vandross A
    Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholesterol management in theory and practice.
    Gotto AM
    Circulation; 1997 Dec; 96(12):4424-30. PubMed ID: 9416913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost implications of lipid-lowering treatments.
    Reckless JP
    Pharmacoeconomics; 1994 Oct; 6(4):310-23. PubMed ID: 10147467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of coronary heart disease with pravastatin.
    Rogers S
    N Engl J Med; 1996 May; 334(20):1333; author reply 1334-5. PubMed ID: 8609956
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The health economics of the treatment of hyperlipidemia and hypertension.
    McMurray J
    Am J Hypertens; 1999 Oct; 12(10 Pt 2):99S-104S. PubMed ID: 10555609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.